#USA #FDA Approval #High Point #commercial manufacturing #Cambrex High Point

Overview

Cambrex, a global leader in contract development and manufacturing organizations (CDMO), has reached a significant milestone by successfully completing three critical pre-approval inspections at its High Point facility in North Carolina. These inspections were conducted by major regulatory authorities, including the U.S. Food and Drug Administration (FDA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and Australia's Therapeutic Goods Administration (TGA). The successful outcome of these inspections allows Cambrex to expand its capabilities in producing approved active pharmaceutical ingredients (APIs) for the U.S, Japan, and Australia, marking High Point as the latest facility in Cambrex's extensive global manufacturing network.

Importance of Pre-Approval Inspections

Pre-Approval Inspections (PAI) are pivotal in the pharmaceutical sector. These thorough evaluations are performed by regulatory bodies to ensure that facilities adhere to stringent quality systems, manufacturing processes, data integrity, and operational controls before granting permission for commercial production. The successful completion of these PAI underscores Cambrex's commitment to quality and operational excellence.

Expansion and Upgrade of High Point Facility

The High Point site underwent a significant $38 million expansion completed in 2023, which included the addition of chemical development and analysis laboratories, clinical manufacturing units, and commercial production facilities equipped with reactors capable of holding up to 2,000 liters each. This upgrade positions High Point as a key player in the production of low-volume commercial products including orphan drugs, precision medicines, and specialized treatments for specific patient populations.

Commitment to Quality and Patient-Centric Solutions

Thomas Loewald, CEO of Cambrex, emphasized the achievement of these inspections as a testament to the robust quality systems in place and the dedication of the High Point team. "As new treatments are developed for targeted patient populations, there's an increasing need for small-scale commercial manufacturing capabilities. High Point was specifically designed to meet this demand, providing clients with an efficient and flexible pathway from development to long-term commercial supply,” he noted.

Comprehensive Development and Manufacturing Network

The High Point facility complements Cambrex's global development and manufacturing network, providing clients with a seamless pathway from process development and clinical manufacturing to commercial production. The establishment of large-scale manufacturing capacity in North Carolina significantly enhances Cambrex's ability to support clients throughout the lifecycle of their products.

About Cambrex

Cambrex is a prominent player in the CDMO market, offering comprehensive active pharmaceutical ingredient development and manufacturing services as well as analytical services throughout the drug lifecycle. With over 45 years of experience and a team of 2,000 experts serving international clients in North America and Europe, Cambrex showcases a wide range of specialized technologies and competencies in pharmaceuticals, including continuous flow production, controlled substances, peptide synthesis, solid-state science, biocatalysis, material characterization, complex compound synthesis, and highly potent active pharmaceutical ingredients (HPAPI).

In conclusion, the successful completion of PAI by Cambrex’s High Point facility not only signifies an important step in regulatory compliance but also enhances the company's ability to serve the evolving needs of the pharmaceutical industry effectively and efficiently. This development is set to play a significant role in meeting the growing demand for specialized treatments across global markets.